New antibiotic agents for bloodstream infections

International Journal of Antimicrobial Agents
Paschalis I Vergidis, Matthew E Falagas

Abstract

Infections due to multidrug-resistant pathogens have shown a dramatic worldwide increase in prevalence. Bloodstream infections (BSIs) represent an important cause of morbidity and mortality in hospitalised patients. Research in the field led to the introduction of several novel antibiotic agents in the fight against bacterial pathogens. New antibiotics used against Gram-positive bacteria, mainly meticillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, include daptomycin, linezolid, quinupristin/dalfopristin and semisynthetic lipoglycopeptides. Among the Gram-negative bacteria, extended-spectrum beta-lactamase-producing Enterobacteriaceae as well as highly resistant Pseudomonas and Acinetobacter isolates are of particular concern. Doripenem is a recently approved carbapenem. Polymyxins are reconsidered as valuable therapeutic options for Gram-negative infections. Tigecycline, a glycylcycline, and ceftobiprole, a novel cephalosporin under investigation, have activity both against Gram-positive and Gram-negative organisms. In addition to the above agents, alternative treatment approaches that require further investigation have also been introduced into clinical practice. These include antibiotic lock therap...Continue Reading

References

Jan 11, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mary C BirminghamJerome J Schentag
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·Ronald N JonesDouglas J Biedenbach
Jan 26, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Issam RaadElyse Seltzer
Oct 1, 2005·The Journal of Antimicrobial Chemotherapy·Andrew F ShorrMarin Kollef
Nov 26, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·T R FritscheR N Jones
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
Dec 26, 2006·The Journal of Infection·Debra D PoutsiakaDavid R Snydman
Jun 7, 2007·The Journal of Antimicrobial Chemotherapy·Matthew E FalagasKonstantinos Z Vardakas
Jul 31, 2007·Future Microbiology·Jordi Vila, Robert A Bonomo
Aug 7, 2007·Expert Review of Anti-infective Therapy·Ioanna P KorbilaMatthew E Falagas

❮ Previous
Next ❯

Citations

May 19, 2011·The Journal of Antibiotics·Mark S Butler, Matthew A Cooper
Oct 2, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Rabia SakaryaSelcuk Kara
Sep 9, 2010·The American Journal of the Medical Sciences·Lee S Engel
Jul 26, 2011·The Lancet Infectious Diseases·Efthimia TasinaMalamatenia Arvanitidou
Mar 15, 2011·Diagnostic Microbiology and Infectious Disease·Francesco LuzzaroGiovanni Gesu
Apr 10, 2009·Critical Reviews in Oncology/hematology·Angiolo GadducciAndrea Riccardo Genazzani
Dec 7, 2010·International Journal of Antimicrobial Agents·Ioannis K NeonakisEfthimia Petinaki
Apr 17, 2012·Peptides·Marie-Paule Mingeot-LeclercqMartti Vaara
Aug 5, 2010·AACN Advanced Critical Care·Kathryn A Connor
Oct 12, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S M S NgC S B Chia
Apr 16, 2021·Journal of Inorganic Biochemistry·Xiang GaoKunjie Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved